

In your trust how many patients with Multiple Sclerosis have been treated with MS disease modifying drugs in the past 6 months, latest 6 months that you can provide.

Please provide the number of patients by treatment for the following disease modifying drugs.

- Aubagio (teriflunomide)
- Avonex (interferon beta-1a)
- Betaferon (interferon beta-1b)
- Copaxone (glatiramer acetate)
- Extavia (beta interferon-1b)
- Gilenya (fingolimod)
- Lemtrada (alemtuzumab)
- Rebif (beta interferon-1a)
- Tecfidera (dimethyl fumarate)
- Tysabri (natalizumab)
- Ampyra (Fampyra)
- Peginterferon beta-1a (Plegridy)
- Daclizumab (Zinbryta)
- Ocrevus (Ocrelizumab)
- Others

In the table below find the total number of patients under the care of Neurology who have been supplied with each of the drugs listed in the last 6 months (November 2016-April 2017) for any indication. The Royal Surrey County Hospital NHS Foundation Trust can only provide the total number of patients treated with the agents listed because the Trust does not record the indication for treatment on the pharmacy dispensing system. **The data may therefore include patients who have been treated with these drug for indications other than those stated in the request.** Where a drug/pack size is not listed it is because we have not supplied it within the specified time frame.

Drug name	Total number of patients treated irrespective of indication
HOMECARE FINGOLIMOD 500 micrograms Capsules	<5
HOMECARE GLATIRAMER ACETATE 20 mg in 1ml Injection	13
HOMECARE GLATIRAMER ACETATE 40 mg in 1ml Injection	<5
HOMECARE INTERFERON BETA-1A (AVONEX) 30 micrograms Injection	6
HOMECARE INTERFERON BETA-1A (AVONEX) 30 micrograms Pre Filled Pen	<5
HOMECARE INTERFERON BETA-1B (BETAFERON) CONTINUATION PACK 300 micrograms in 1.2ml (9.6 million units) Powder and Solvent	<5